News

9

Sep, 2020

Actual problems of HIV Infection: Mother and Child

Tags: ,

Penta has been invited to run a one-day session at the Republican Hospital of Infectious Diseases, St Petersburg conference on ‘Actual problems of HIV Infection: Mother and Child’ on Tuesday 15th September. The Penta session What’s new for children and women living with HIV: interactive clinical day with Penta will look at new data on ART in pregnancy and newborns, resistance and recommendations for 1st, 2nd and further lines, supporting our adolescents and coinfections. Register to conference!

READ MORE

1

Jul, 2020

ODYSSEY (Penta 20) trial plays an important role in the FDA approval of dolutegravir for children – a big step towards timely access to optimal ART for children

Tags: ,

Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. Food and Drug Administration (FDA) of the adult formulation for children weighing ≥20kg and dolutegravir (DTG) dispersible tablets for children of 4 weeks of age and older.

READ MORE

6

Mar, 2020

Penta at CROI 2020

Tags: , ,

The annual Conference on Retroviruses and Opportunistic Infections (CROI) will be held from March 8 to 11 in Boston, Massachusetts.

CROI brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.

READ MORE

4

Mar, 2020

Penta at 10th International Workshop on HIV & Women

Tags: ,

The 10th International Workshop on HIV & Women is in Boston on 6 – 7 March 2020, just prior to CROI. This is an outstanding opportunity for health care providers, researchers, government, industry and community representatives to discuss, debate, and increase their knowledge on HIV and its burden on women. 

READ MORE

28

Feb, 2020

ushr: Understanding suppression of HIV in R

Tags: , ,

Authors: Morris SE, Dziobek-Garrett L, Yates AJ and the EPIICAL consortium Published in: BMC Bioinformatics 2020;21(1):52 Background HIV/AIDS is responsible for the deaths of one million people every year. Although mathematical modeling has provided many insights into the dynamics of HIV infection, there is still a lack of accessible tools for researchers unfamiliar with modeling techniques to apply them to their own clinical data. Results Here we present ushr, a free and open-source R package that models the decline of HIV during antiretroviral treatment (ART) using a popular mathematical framework. […]

READ MORE

19

Feb, 2020

New publications from EPIICAL Consortium

Tags: , ,

Just published – data on T & B cell memory and T cell function in early-treated children in the Journal of Immunology and AIDS. Antiretroviral treatment (if started at an early stage) is able to reduce the amount of HIV virus in a child’s body. EPIICAL is studying the characteristics of the immune response and the amount of HIV virus, in children with HIV who are treated at an early stage. This is to outline treatment strategies to help find a cure for HIV. Congratulations to all the authors!

READ MORE

19

Feb, 2020

Impact of early antiretroviral therapy initiation on HIV-specific CD4 and CD8 T cell function in perinatally infected children

Tags: ,

Authors: Rinaldi S, Pallikkuth S, Cameron M, et al. Published in: J Immunol. 2020 Feb 1;204:540-549 Abstract Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children limits the size of the virus reservoir, but whether the time of treatment initiation (TI) can durably impact host immune responses associated with HIV infection is still unknown. This study was conducted in PBMC of 20 HIV-infected virally suppressed children on ART (mean age 9.4 y), classified as early treated (ET; age at ART initiation ≤0.5 y, n = 14) or late treated (LT; […]

READ MORE